©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Aug 15, 2022; 14(8): 1540-1551
Published online Aug 15, 2022. doi: 10.4251/wjgo.v14.i8.1540
Published online Aug 15, 2022. doi: 10.4251/wjgo.v14.i8.1540
Adjuvant chemoradiotherapy vs adjuvant chemotherapy in locally advanced Siewert type II/III adenocarcinoma of gastroesophageal junction after D2/R0 resection
Wen-Zhe Kang, Jian-Ping Xiong, Xin-Xin Shao, Hai-Tao Hu, Yan-Tao Tian, Department of Pancreatic and Gastric Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
Jin-Ming Shi, Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
Bing-Zhi Wang, Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
Jing Jin, Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen 518116, Guangdong Province, China
Author contributions: Tian YT and Jin J designed the research; Kang WZ, Shi JM, Wang BZ, Xiong JP and Shao XX analyzed the data and wrote the paper; Hu HT collected the patient’s clinical data; Kang WZ and Shi JM contributed equally to this work.
Supported by National Natural Science Foundation of China , No. 82072734 .
Institutional review board statement: The study was reviewed and approved by the National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Institutional Review Board, No. 17-156/1412.
Informed consent statement: Patients were not required to give informed consent to the study because the analysis used anonymous data that were obtained after each patient agreed to treatment by written consent.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: Dataset available from the first author at kwz@whu.edu.cn.
Corresponding author: Yan-Tao Tian, PhD, Professor, Department of Pancreatic and Gastric Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing 100021, China. tianyantao@cicams.ac.cn
Received: May 6, 2022
Peer-review started: May 6, 2022
First decision: June 12, 2022
Revised: June 19, 2022
Accepted: July 22, 2022
Article in press: July 22, 2022
Published online: August 15, 2022
Processing time: 96 Days and 2.6 Hours
Peer-review started: May 6, 2022
First decision: June 12, 2022
Revised: June 19, 2022
Accepted: July 22, 2022
Article in press: July 22, 2022
Published online: August 15, 2022
Processing time: 96 Days and 2.6 Hours
Core Tip
Core Tip: This is a retrospective study to investigate the value of adjuvant chemoradiotherapy (CRT) in locally advanced Siewert type II/III adenocarcinoma of gastroesophageal junction. We identified 316 such patients and followed their overall survival (OS), relapse-free survival, and recurrence pattern. Our study found that for locally advanced Siewert type III gastroesophageal junction, adjuvant CRT may prolong OS and reduce the regional recurrence rate.